The GLO1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblast cell line, designed to disrupt the GLO1 gene. This product provides a loss-of-function model for studying glyoxalase 1, a critical enzyme in methylglyoxal detoxification. The polyclonal nature ensures a heterogeneous knockout population representing a range of target-gene disruptions, enabling robust functional studies.
The Raji cell line is an Epstein-Barr virus (EBV)-positive B lymphocyte model established from a Burkitt lymphoma patient. These cells exhibit surface IgM and kappa light chain expression and lack EBNA2, making them a widely used system for investigating B cell biology, lymphomagenesis, and EBV-driven oncogenic mechanisms. The Raji line is particularly relevant for cancer metabolism research given its high glycolytic activity typical of Burkitt lymphoma.
GLO1 catalyzes the glutathione-dependent conversion of methylglyoxal, a reactive dicarbonyl glycolysis byproduct, to S-D-lactoylglutathione, which is hydrolyzed by GLO2 (HAGH) to D-lactate, regenerating glutathione. This detoxification pathway prevents accumulation of methylglyoxal and formation of advanced glycation end-products (AGEs), protecting cells from carbonyl stress, protein crosslinking, and RAGE-mediated signaling. Transcriptionally, GLO1 is regulated by NFE2L2 (Nrf2) under oxidative stress and by HIF1A and AP-1 (JUN/FOS) in metabolic and oncogenic contexts. By maintaining glutathione homeostasis and attenuating apoptosis, GLO1 is integral to redox balance.
In Raji cells, which exhibit heightened glycolysis and are susceptible to oxidative stress associated with EBV-driven proliferation, disruption of GLO1 provides a powerful tool to dissect the interplay between glyoxalase activity and lymphomagenesis. This polyclonal knockout model allows researchers to examine how loss of GLO1 impacts methylglyoxal accumulation, glutathione levels, and AGE-induced activation of NF-??B signaling, a pathway frequently dysregulated in B cell malignancies. Furthermore, the model is instrumental for evaluating chemoresistance mechanisms, as elevated GLO1 activity has been implicated in cancer cell survival under chemotherapy-induced stress.
Typical applications include assessing cell viability and apoptosis under carbonyl stress using MTT or Annexin V assays, quantifying methylglyoxal and glutathione levels by LC-MS or enzymatic assays, and measuring ROS by flow cytometry. Researchers can also perform Western blotting and RT-qPCR for GLO1 expression analysis and drug sensitivity screens to identify GLO1-dependent vulnerabilities. This model is well-suited for diabetic complication and glycation stress studies. For further information or custom projects, contact Ascent Research.
